Gilde Healthcare company GT Medical Technologies acquires radioactive seed assets from Perspective Therapeutics, Inc. - Gilde Healthcare

Gilde Healthcare company GT Medical Technologies acquires radioactive seed assets from Perspective Therapeutics, Inc.

December 12, 2023
Tempe, Ariz. and Seattle (USA) & Utrecht (the Netherlands)

GT Medical Technologies, Inc., a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced it has agreed to acquire substantially all of the radioactive Cesium-131 seed assets and related business infrastructure from Isoray Medical, which is a subsidiary of Perspective Therapeutics, Inc. (“Isoray”). GT Medical Technologies’ GammaTile Therapy is FDA-cleared to treat patients with operable brain tumors to eliminate residual tumor cells. Full market release for this technology occurred in March 2020, and over 100 leading brain tumor treatment centers have adopted GammaTile to date. The transaction is expected to decrease the required lead times from the customer order to product delivery, allowing even more patients to benefit from this game-changing technology. The closing of the transaction is subject to satisfaction of customary conditions to closing and is expected to close in the first quarter of 2024.

The acquisition would strengthen GT Medical Technologies’ position in the market by ensuring access to and control of radioactive seed production. The seeds are a key component of GammaTile Therapy for patients undergoing brain tumor resection surgeries with the need for adjuvant radiation therapy. In addition, the acquisition has the potential to expand GT Medical Technologies’ customer base to include multiple facilities treating patients with prostate, lung, head & neck, and gynecological tumors.

GammaTile consists of bioresorbable collagen embedded with Cesium-131 radioactive seeds. This Surgically Targeted Radiation Therapy (STaRT) starts radiation immediately after tumor removal to help eradicate residual tumor cells.

About GT Medical Technologies, Inc.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. GammaTile is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in the United States in March 2020, GammaTile has been offered in over 100 leading institutions, with more centers being added each month. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a diversified medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. Perspective Therapeutics has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. Perspective Therapeutics is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Perspective Therapeutics’ melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. Perspective Therapeutics has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit Perspective Therapeutics’ website at www.perspectivetherapeutics.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
March 21, 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
March 18, 2024